E-viri
Recenzirano
-
Rabinovici, Gil D; La Joie, Renaud
JAMA : the journal of the American Medical Association, 08/2023, Letnik: 330, Številka: 6Journal Article
Novel biomarkers measuring amyloid-β (Aβ) and phosphorylated tau (P-tau) have aided in the early detection and diagnosis of Alzheimer's disease (AD). Clinical trials are testing therapeutics that modify AD biology, using biomarkers to select patients, assess target engagement, and evaluate therapy effects on AD pathophysiology. The first therapies to reach the clinic are monoclonal antibodies targeting Aβ, based on the "amyloid hypothesis" that Aβ aggregation triggers a cascade of pathophysiologic events leading to cognitive decline and dementia. Monoclonal antibodies bind Aβ aggregates, promoting their clearance from the brain and potentially slowing cognitive decline.
